Abstract：
BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, prognosis, disease monitoring, and prediction of treatment efficacy. In this review, we focus on important advances as well as future efforts needed to drive clinical innovation in this area of urine biomarker research for prostate cancer detection and prognostication. METHODS:We provide a review of current literature on urinary biomarkers for prostate cancer. We evaluate the strengths and limitations of a variety of approaches that vary in sampling strategies and targets measured; discuss reported urine tests for prostate cancer with respect to their technical, analytical, and clinical parameters; and provide our perspectives on critical considerations in approaches to developing a urine-based test for prostate cancer. RESULTS:There has been an extensive history of exploring urine as a source of biomarkers for prostate cancer that has resulted in a variety of urine tests that are in current clinical use. Importantly, at least three tests have demonstrated high sensitivity (~90%) and negative predictive value (~95%) for clinically significant tumors; however, there has not been widespread adoption of these tests. CONCLUSIONS:Conceptual and methodological advances in the field will help to drive the development of novel urinary tests that in turn may lead to a shift in the clinical paradigm for prostate cancer diagnosis and management.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo Jdoi
10.1038/s41391-019-0127-4subject
Has Abstractpub_date
2019-09-01 00:00:00pages
362-381issue
3eissn
1365-7852issn
1476-5608pii
10.1038/s41391-019-0127-4journal_volume
22pub_type
杂志文章,评审abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-020-0234-2
更新日期：2020-12-01 00:00:00
abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500471
更新日期：2000-12-01 00:00:00
abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2016.40
更新日期：2016-12-01 00:00:00
abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-018-0041-1
更新日期：2018-09-01 00:00:00
abstract：:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2010.26
更新日期：2010-12-01 00:00:00
abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500552
更新日期：2002-01-01 00:00:00
abstract：:As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literatu...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500857
更新日期：2006-01-01 00:00:00
abstract：:The present study seeks to establish a relationship between the quality of a surgical procedure and the subsequent hospital costs for that procedure by investigating the influence of both patient and peri-operative factors on the hospital costs of radical prostatectomy. All men who underwent radical prostatectomy at o...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500529
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0096-z
更新日期：2019-03-01 00:00:00
abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.28
更新日期：2014-12-01 00:00:00
abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500412
更新日期：2000-11-01 00:00:00
abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,随机对照试验
doi：10.1038/s41391-017-0030-9
更新日期：2018-06-01 00:00:00
abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究
doi：10.1038/pcan.2014.41
更新日期：2015-03-01 00:00:00
abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0064-7
更新日期：2018-11-01 00:00:00
abstract：:The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.14
更新日期：2011-09-01 00:00:00
abstract：:The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2010.4
更新日期：2010-06-01 00:00:00
abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500752
更新日期：2004-01-01 00:00:00
abstract：:The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prost...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500620
更新日期：2002-01-01 00:00:00
abstract：:An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2015.31
更新日期：2016-03-01 00:00:00
abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500839
更新日期：2006-01-01 00:00:00
abstract：:The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500295
更新日期：1999-03-01 00:00:00
abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-020-0258-7
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1038/pcan.2012.12
更新日期：2012-09-01 00:00:00
abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500326
更新日期：1999-12-01 00:00:00
abstract：BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.55
更新日期：2017-03-01 00:00:00
abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,已发布勘误
doi：10.1038/pcan.2017.35
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-019-0161-2
更新日期：2020-03-01 00:00:00
abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500779
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.53
更新日期：2012-03-01 00:00:00
abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...
journal_title：Prostate cancer and prostatic diseases
pub_type： 临床试验,杂志文章
doi：10.1038/pcan.2015.55
更新日期：2016-03-01 00:00:00
